United States 
United States
TriLink BioTechnologies specializes in the synthesis of highly modified nucleic acid constructs for research, diagnostic, and therapeutic applications. Since 1996, TriLink has offered cutting edge products to researchers in the fields of gene therapy, nucleoside chemotherapy, oligonucleotide therapy, next generation sequencing, vaccines, and diagnostics. The company manufactures with industry-leading technology, consistent high quality, and ready access to expert scientific support when needed. TriLink develops and manufactures oligonucleotides, mRNA transcripts, nucleotides, bioconjugation, custom chemistry, solutions for PCR & RT-PCR, and NGS library preparation kits. The oligonucleotide and mRNA solutions offered have enabled significant advancements in the biological sciences. TriLink is expanding their manufacturing potential with a new global headquarters, set to open in Fall 2019 in San Diego, CA, learn more here. A privately held company, TriLink BioTechnologies was acquired by Maravai LifeSciences in 2017. See maravai.com to learn more.
Founded in May in San Diego, California. By year-end, TriLink moves into first commercial lab space, begins shipping oligonucleotides, and hires first employees.
Obtains license to synthesize radioactive compounds. TriLink quickly becomes the industry leader and one of the only companies in the world to successfully manufacture radio-labeled oligos.
First customer-written paper citing TriLink products is published in the Journal of Immunology by David Broide et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice.
Expands into nucleoside triphosphates. Cofounds Solulink®, a company focused on unique bioconjugation chemistries. Outgrows first lab and expands to Nancy Ridge site. First paper under TriLink corporate name is published.
Company continues to experience remarkable growth and expands to a 40,000 square foot building that served as the corporate headquarters.
Receives first of four SBIR grants for chemically modified primers and NTPs for improved hot-start PCR, the basis of the CleanAmp® product line.
Proven pre-clinical oligo production leads to first alliance partnership with large therapeutic oligo CMO, enabling customers to easily transition from R&D to clinical trials.
Leverages expertise with complicated nucleic acids and begins IVT production of long RNA and mRNA for use in pharmaceutical research and development. First patent for CleanAmp® is granted.
Receives ISO 9001 certification. Opens state-of-the-art GMP manufacturing facility and expands into mRNA and oligonucleotide therapeutics. Secures contract for synthesis of Ebola vaccine with Battelle. Awarded patents for proprietary CleanTag® technology.
Publications citing TriLink products exceeds 6,000. Adds gram scale mRNA production and expands mRNA purification offerings. Launches CleanTag® Small RNA Library Prep kits. Cofounds ETAGEN, a company focused on gene editing technologies, with Tod Woolf.
Strategic investment by Maravai LifeSciences.
Launches CleanCap® - a patented mRNA capping method that makes remarkable improvements over existing technology.
Receives ISO 9001:2015 certification.
TriLink & Maravai move to new global headquarters. Space includes 105,000 sq. ft. facility space with 50,000 sq. ft. of custom manufacturing space, including 5 GMP suites.
